## David E Kleiner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8828754/publications.pdf

Version: 2024-02-01

510 papers 65,068 citations

112 h-index 932 240 g-index

519 all docs

519 docs citations

519 times ranked

56124 citing authors

#	Article	IF	CITATIONS
1	Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology, 2005, 41, 1313-1321.	7.3	8,518
2	Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis. New England Journal of Medicine, 2010, 362, 1675-1685.	27.0	2,718
3	Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2015, 149, 389-397.e10.	1.3	2,200
4	Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet, The, 2015, 385, 956-965.	13.7	1,840
5	MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158, 1999-2014.e1.	1.3	1,840
6	Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell, 2017, 169, 1327-1341.e23.	28.9	1,794
7	Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology, 2010, 51, 121-129.	7.3	1,078
8	Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology, 2011, 53, 810-820.	7.3	941
9	Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and Adolescents. JAMA - Journal of the American Medical Association, 2011, 305, 1659.	7.4	926
10	Quantitative Zymography: Detection of Picogram Quantities of Gelatinases. Analytical Biochemistry, 1994, 218, 325-329.	2.4	810
11	Enterocolitis in Patients With Cancer After Antibody Blockade of Cytotoxic T-Lymphocyte–Associated Antigen 4. Journal of Clinical Oncology, 2006, 24, 2283-2289.	1.6	794
12	Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i> Science, 2014, 345, 1623-1627.	12.6	745
13	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine, 2014, 370, 911-920.	27.0	687
14	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 2004, 39, 188-196.	7.3	679
15	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. Journal of Hepatology, 2017, 66, 545-551.	3.7	624
16	Matrix metalloproteinases and metastasis. Cancer Chemotherapy and Pharmacology, 1999, 43, S42-S51.	2.3	621
17	Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology, 2011, 54, 344-353.	7.3	617
18	Hepatic Failure and Lactic Acidosis Due to Fialuridine (FIAU), an Investigational Nucleoside Analogue for Chronic Hepatitis B. New England Journal of Medicine, 1995, 333, 1099-1105.	27.0	593

#	Article	IF	CITATIONS
19	Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB Journal, 1993, 7, 1434-1441.	0.5	554
20	NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 2016, 531, 253-257.	27.8	552
21	SARS-CoV-2 infection of the oral cavity and saliva. Nature Medicine, 2021, 27, 892-903.	30.7	527
22	Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study. Annals of Surgical Oncology, 2005, 12, 1005-1016.	1.5	477
23	Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. EClinicalMedicine, 2020, 24, 100434.	7.1	465
24	Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1. Gastroenterology, 2006, 131, 470-477.	1.3	453
25	Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer. Cancer Cell, 2019, 36, 418-430.e6.	16.8	433
26	Gastrointestinal Involvement in Chronic Granulomatous Disease. Pediatrics, 2004, 114, 462-468.	2.1	427
27	Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 31-47.	2.0	427
28	Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Reports, 2017, 18, 2780-2794.	6.4	416
29	RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H). Transplantation, 2003, 76, 120-129.	1.0	413
30	Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. New England Journal of Medicine, 2021, 385, 1559-1569.	27.0	406
31	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 894-903.	7.3	403
32	The Banff 2007 Working Classification of Skin-Containing Composite Tissue Allograft Pathology. American Journal of Transplantation, 2008, 8, 1396-1400.	4.7	397
33	Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology, 2010, 52, 913-924.	7.3	397
34	Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003, 124, 97-104.	1.3	368
35	Structural biochemistry and activation of matrix metalloproteases. Current Opinion in Cell Biology, 1993, 5, 891-897.	5.4	335
36	Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology, 2009, 49, 809-820.	7.3	335

#	Article	IF	CITATIONS
37	Long-Term Therapy of Chronic Hepatitis B With Lamivudine. Hepatology, 2000, 32, 828-834.	7.3	326
38	Hepatic histological findings in suspected drugâ€induced liver injury: Systematic evaluation and clinical associations. Hepatology, 2014, 59, 661-670.	7.3	322
39	Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 156-163.e2.	4.4	322
40	Analysis of Factors Associated With Outcome in Patients With Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy. Journal of Clinical Oncology, 2003, 21, 4560-4567.	1.6	321
41	Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research. Seminars in Liver Disease, 2012, 32, 003-013.	3.6	321
42	Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology, 1997, 113, 1660-1667.	1.3	315
43	Ribavirin as Therapy for Chronic Hepatitis C. Annals of Internal Medicine, 1995, 123, 897.	3.9	310
44	Acute Hepatitis E Infection Accounts for Some Cases of Suspected Drug-Induced Liver Injury. Gastroenterology, 2011, 141, 1665-1672.e9.	1.3	294
45	The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology, 2011, 54, 931-939.	7.3	279
46	10-year follow-up after interferon-? therapy for chronic hepatitis C. Hepatology, 1998, 28, 1121-1127.	7.3	275
47	Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection. Gastroenterology, 2011, 141, 1220-1230.e3.	1.3	268
48	Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes. Annals of Internal Medicine, 2000, 133, 263.	3.9	265
49	Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics. JAMA - Journal of the American Medical Association, 2013, 310, 804.	7.4	265
50	Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology, 2011, 53, 448-457.	7.3	261
51	Galectin-3 Is a Novel Substrate for Human Matrix Metalloproteinases-2 and -9. Biochemistry, 1994, 33, 14109-14114.	2.5	251
52	Clinical trial: pilot study of metformin for the treatment of nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2009, 29, 172-182.	3.7	249
53	Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. Cancer Immunology Research, 2016, 4, 419-430.	3.4	247
54	Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology, 2010, 51, 201-209.	7.3	245

#	Article	IF	CITATIONS
55	Volunteer Blood Donors with Antibody to Hepatitis C Virus: Clinical, Biochemical, Virologic, and Histologic Features. Annals of Internal Medicine, 1995, 123, 330.	3.9	239
56	Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Network Open, 2019, 2, e1912565.	5.9	230
57	NIH Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. The 2014 Pathology Working Group Report. Biology of Blood and Marrow Transplantation, 2015, 21, 589-603.	2.0	228
58	The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology, 2007, 46, 424-429.	7.3	227
59	Hepatocellular Carcinoma Confirmation, Treatment, and Survival in Surveillance, Epidemiology, and End Results Registries, 1992-2008. Hepatology, 2012, 55, 476-482.	7.3	226
60	Clinical Correlates of Histopathology in Pediatric Nonalcoholic Steatohepatitis. Gastroenterology, 2008, 135, 1961-1971.e2.	1.3	225
61	Nodular regenerative hyperplasia: Not all nodules are created equal. Hepatology, 2006, 44, 7-14.	7.3	222
62	Redefined clinical features and diagnostic criteria in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. JCI Insight, 2016, 1, .	5.0	219
63	Peripheral CD4+CD8+ T cells are differentiated effector memory cells with antiviral functions. Blood, 2004, 104, 478-486.	1.4	218
64	Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism: Clinical and Experimental, 2016, 65, 1080-1086.	3.4	218
65	Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clinics in Liver Disease, 2016, 20, 293-312.	2.1	217
66	Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infectious Diseases, The, 2015, 15, 1167-1174.	9.1	216
67	Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology, 2005, 41, 753-760.	7.3	210
68	Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis. Gastroenterology, 2017, 153, 753-761.	1.3	209
69	Validation of a model of colon cancer progression. Journal of Pathology, 2000, 192, 446-454.	4.5	208
70	A Spectrum of Severe Familial Liver Disorders Associate with Telomerase Mutations. PLoS ONE, 2009, 4, e7926.	2.5	201
71	Spectrum of statin hepatotoxicity: Experience of the drug-induced liver injury network. Hepatology, 2014, 60, 679-686.	7.3	200
72	Acute GVHD in patients receiving IL-15/4-1BBL activated NK cells following T-cell–depleted stem cell transplantation. Blood, 2015, 125, 784-792.	1.4	200

#	Article	IF	Citations
73	17â€Beta Hydroxysteroid Dehydrogenase 13Âls a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 1504-1519.	7.3	200
74	Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2008, 48, 829-834.	3.7	194
75	Performance characteristics of vibrationâ€controlled transient elastography for evaluation of nonalcoholic fatty liver disease. Hepatology, 2018, 67, 134-144.	7.3	192
76	Liver Injury From Tumor Necrosis Factor- $\hat{l}_{\pm}$ Antagonists: Analysis of Thirty-four Cases. Clinical Gastroenterology and Hepatology, 2013, 11, 558-564.e3.	4.4	187
77	Virologic Response Following Combined Ledipasvir and Sofosbuvir Administration in Patients With HCV Genotype 1 and HIV Co-infection. JAMA - Journal of the American Medical Association, 2015, 313, 1232.	7.4	186
78	MMP-2: Expression, Activation and Inhibition. Enzyme & Protein, 1996, 49, 7-19.	1.4	183
79	Hepatitis B Virus–Specific and Global T-Cell Dysfunction in Chronic Hepatitis B. Gastroenterology, 2016, 150, 684-695.e5.	1.3	178
80	Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology, 2007, 45, 80-87.	7.3	165
81	Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. Blood, 2011, 117, 4787-4795.	1.4	165
82	Vitamin <scp>E</scp> and changes in serum alanine aminotransferase levels in patients with nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2013, 38, 134-143.	3.7	163
83	Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care, 2015, 38, 1347-1355.	8.6	162
84	Quantitative Reverse Zymography: Analysis of Picogram Amounts of Metalloproteinase Inhibitors Using Gelatinase A and B Reverse Zymograms. Analytical Biochemistry, 1997, 244, 161-166.	2.4	160
85	Prognostic value of Ishak fibrosis stage: Findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology, 2010, 51, 585-594.	7.3	155
86	Modeling Pathogenesis of Primary Liver Cancer in Lineage-Specific Mouse Cell Types. Gastroenterology, 2013, 145, 221-231.	1.3	153
87	Lamivudine for chronic delta hepatitis. Hepatology, 1999, 30, 546-549.	7.3	152
88	Malignant insulinoma. Cancer, 2005, 104, 264-272.	4.1	150
89	Causes of death in hyper-IgE syndrome. Journal of Allergy and Clinical Immunology, 2007, 119, 1234-1240.	2.9	149
90	Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Lancet, The, 2015, 385, 1107-1113.	13.7	148

#	Article	IF	Citations
91	Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. Hepatology, 2013, 58, 1644-1654.	7.3	146
92	Histological Abnormalities in Children with Nonalcoholic Fatty Liver Disease and Normal or Mildly Elevated Alanine Aminotransferase Levels. Journal of Pediatrics, 2014, 164, 707-713.e3.	1.8	146
93	Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. Clinical Gastroenterology and Hepatology, 2019, 17, 1877-1885.e5.	4.4	145
94	Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clinical Gastroenterology and Hepatology, 2017, 15, 103-112.e2.	4.4	144
95	Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design. Contemporary Clinical Trials, 2009, 30, 88-96.	1.8	140
96	Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Human Pathology, 2004, 35, 196-199.	2.0	139
97	The liver diseases of lipodystrophy: The long-term effect of leptin treatment. Journal of Hepatology, 2013, 59, 131-137.	3.7	138
98	Host-Dependent Patterns of Tissue Injury in Invasive Pulmonary Aspergillosis. American Journal of Clinical Pathology, 2007, 127, 349-355.	0.7	137
99	Predictors of Acquired Lipodystrophy in Juvenile-Onset Dermatomyositis and a Gradient of Severity. Medicine (United States), 2008, 87, 70-86.	1.0	137
100	Long-Term Follow-Up of Chimpanzees Inoculated with the First Infectious Clone for Hepatitis C Virus. Journal of Virology, 1999, 73, 3317-3325.	3.4	137
101	Resolution of chronic delta hepatitis after 12 years of interferon alfa therapy. Gastroenterology, 1999, 117, 1229-1233.	1.3	135
102	Renal tubular dysfunction during longâ€term adefovir or tenofovir therapy in chronic hepatitis <scp>B</scp> . Alimentary Pharmacology and Therapeutics, 2012, 35, 1317-1325.	3.7	135
103	Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 75, 1397-1408.	3.7	133
104	Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma. Digestive Diseases and Sciences, 2012, 57, 2233-2240.	2.3	131
105	Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clinical and Experimental Metastasis, 1998, 16, 217-225.	3.3	129
106	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. Oncologist, 2019, 24, 1259-1269.	3.7	127
107	Functionally Significant Renal Allograft Rejection Is Defined by Transcriptional Criteria. American Journal of Transplantation, 2005, 5, 573-581.	4.7	125
108	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	7.3	125

#	Article	IF	CITATIONS
109	Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology, 2003, 124, 352-360.	1.3	124
110	Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex. Kidney International, 1993, 43, 163-170.	5.2	120
111	Hepatic Abscess in Patients With Chronic Granulomatous Disease. Annals of Surgery, 2002, 235, 383-391.	4.2	119
112	NASH and cryptogenic cirrhosis: A histological analysis. Annals of Hepatology, 2009, 8, 346-352.	1.5	117
113	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. Cancer Discovery, 2021, 11, 1248-1267.	9.4	117
114	Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet, The, 2002, 360, 1662-1664.	13.7	116
115	Results from a Human Renal Allograft Tolerance Trial Evaluating T-Cell Depletion with Alemtuzumab Combined with Deoxyspergualin. Transplantation, 2005, 80, 1051-1059.	1.0	115
116	Monocyte Infiltration and Kidney Allograft Dysfunction During Acute Rejection. American Journal of Transplantation, 2008, 8, 600-607.	4.7	112
117	Nodular Regenerative Hyperplasia in Common Variable Immunodeficiency. Journal of Clinical Immunology, 2013, 33, 748-758.	3.8	112
118	Diagnostic accuracy of magnetic resonance imaging hepatic proton density fat fraction in pediatric nonalcoholic fatty liver disease. Hepatology, 2018, 67, 858-872.	7.3	112
119	Among Patients With Nonalcoholic Fatty Liver Disease, Modest Alcohol Use Is Associated With Less Improvement in Histologic Steatosis and Steatohepatitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1511-1520.e5.	4.4	111
120	BK virus and SV40 co-infection in polyomavirus nehropathy1. Transplantation, 2002, 74, 1497-1504.	1.0	110
121	High Prevalence of Nonalcoholic Fatty Liver Disease in Adolescents Undergoing Bariatric Surgery. Gastroenterology, 2015, 149, 623-634.e8.	1.3	110
122	Cancers as Wounds that Do Not Heal: Differences and Similarities between Renal Regeneration/Repair and Renal Cell Carcinoma. Cancer Research, 2006, 66, 7216-7224.	0.9	109
123	The Pathology of Drug-Induced Liver Injury. Seminars in Liver Disease, 2009, 29, 364-372.	3.6	107
124	Clinical and Histopathologic Features of Fluoroquinolone-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2011, 9, 517-523.e3.	4.4	107
125	Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology, 2019, 70, 522-531.	7.3	106
126	Cyclical Cushing Syndrome Presenting in Infancy: An Early Form of Primary Pigmented Nodular Adrenocortical Disease, or a New Entity?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3173-3182.	3.6	105

#	Article	IF	CITATIONS
127	Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology, 2017, 65, 1267-1277.	7.3	105
128	Molecular Evaluation of BK Polyomavirus Nephropathy. American Journal of Transplantation, 2005, 5, 2883-2893.	4.7	104
129	Liver biopsy findings in chronic hepatitis B. Hepatology, 2009, 49, S61-S71.	7.3	104
130	Invasive Aspergillosis Due to <i>Neosartorya udagawae</i> . Clinical Infectious Diseases, 2009, 49, 102-111.	5.8	103
131	Hepatic abnormalities in patients with chronic granulomatous disease. Hepatology, 2007, 45, 675-683.	7.3	102
132	In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores. Gastroenterology, 2016, 151, 1141-1154.e9.	1.3	100
133	Biophysical and Functional Characterization of Full-length, Recombinant Human Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Produced in Escherichia coli. Journal of Biological Chemistry, 1999, 274, 21362-21368.	3.4	99
134	Relationship Between Changes in Serum Levels of Keratin 18 and Changes in Liver Histology in Children and Adults With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 2121-2130.e2.	4.4	97
135	The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunology, Immunotherapy, 2019, 68, 599-608.	4.2	97
136	Clinical Spectrum and Histopathologic Features of Chronic Hepatitis C Infection in Children. Journal of Pediatrics, 2007, 150, 168-174.e1.	1.8	96
137	Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 823-834.	2.8	96
138	Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis. Hepatology, 2013, 58, 1548-1557.	7.3	96
139	Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases*1. Hepatology, 1995, 22, 1163-1170.	7.3	95
140	Molecular and immunohistochemical characterization of the onset and resolution of human renal allograft ischemia-reperfusion injury. Transplantation, 2002, 74, 916-923.	1.0	95
141	Clinical and Histologic Features of Azithromycin-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2015, 13, 369-376.e3.	4.4	95
142	Amoxicillin–Clavulanate-Induced Liver Injury. Digestive Diseases and Sciences, 2016, 61, 2406-2416.	2.3	92
143	APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors. Cell Reports, 2019, 26, 2651-2666.e6.	6.4	92
144	Insights into pathogenesis of fatal COVIDâ€19 pneumonia from histopathology with immunohistochemical and viral RNA studies. Histopathology, 2020, 77, 915-925.	2.9	92

#	Article	IF	CITATIONS
145	Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children. Journal of Pediatrics, 2017, 187, 141-146.e1.	1.8	91
146	Changes in Serum Adipokine Levels During Pioglitazone Treatment for Nonalcoholic Steatohepatitis: Relationship to Histological Improvement. Clinical Gastroenterology and Hepatology, 2006, 4, 1048-1052.	4.4	90
147	Long-term therapy of chronic delta hepatitis with peginterferon alfa. Alimentary Pharmacology and Therapeutics, 2014, 40, 93-104.	3.7	90
148	Characteristics of Adults in the Hepatitis B Research Network in North America Reflect Their Country of Origin and Hepatitis B Virus Genotype. Clinical Gastroenterology and Hepatology, 2015, 13, 183-192.	4.4	90
149	Composite Tissue Allotransplantation: Classification of Clinical Acute Skin Rejection. Transplantation, 2005, 80, 1676-1680.	1.0	88
150	Long term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterology, 2014, 14, 166.	2.0	87
151	Adrenocortical Neoplasms: Role of Prognostic Markers MIB-1, P53, and RB. American Journal of Surgical Pathology, 1997, 21, 556-562.	3.7	87
152	NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology, 2021, 73, 2028-2038.	7.3	86
153	Unusual aspects of allergic bronchopulmonary fungal disease: Report of two cases due to Curularia organisms associated with allergic fungal sinusitis. Human Pathology, 1991, 22, 1240-1248.	2.0	85
154	Characteristics of Idiosyncratic Drugâ€induced Liver Injury in Children. Journal of Pediatric Gastroenterology and Nutrition, 2011, 53, 182-189.	1.8	85
155	Comparative analysis of portal hepatic infiltrating leucocytes in acute drug-induced liver injury, idiopathic autoimmune and viral hepatitis. Clinical and Experimental Immunology, 2015, 180, 40-51.	2.6	85
156	Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury. American Journal of Gastroenterology, 2015, 110, 1450-1459.	0.4	85
157	Hepatic Involvement and Portal Hypertension Predict Mortality in Chronic Granulomatous Disease. Gastroenterology, 2008, 134, 1917-1926.	1.3	84
158	Molecular regulation of cellular invasionâ€" role of gelatinase A and TIMP-2. Biochemistry and Cell Biology, 1996, 74, 823-831.	2.0	83
159	Prevalence and clinical significance of lymphocytic foci in minor salivary glands of healthy volunteers. Arthritis and Rheumatism, 2002, 47, 520-524.	6.7	83
160	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology, 2003, 38, 66-74.	7.3	83
161	Nonalcoholic Steatohepatitis and Hepatic Fibrosis in HIV-1-Monoinfected Adults With Elevated Aminotransferase Levels on Antiretroviral Therapy. Clinical Infectious Diseases, 2015, 60, 1569-78.	5 <b>.</b> 8	81
162	Stability analysis of latent and active 72-kDa type IV collagenase: The role of tissue inhibitor of metalloproteinases-2 (TIMP-2). Biochemistry, 1993, 32, 1583-1592.	2.5	80

#	Article	IF	Citations
163	Composite Tissue Allotransplantation: Development of a Preclinical Model in Nonhuman Primates. Transplantation, 2005, 80, 1447-1454.	1.0	79
164	Salivary Gland Involvement in Chronic Graft-Versus-Host Disease: Prevalence, Clinical Significance, and Recommendations for Evaluation. Biology of Blood and Marrow Transplantation, 2010, 16, 1362-1369.	2.0	79
165	Simtuzumab treatment of advanced liver fibrosis in <scp>HIV</scp> and <scp>HCV</scp> â€infected adults: results of a 6â€month openâ€label safety trial. Liver International, 2016, 36, 1783-1792.	3.9	79
166	Adultâ€onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. Hepatology, 2017, 66, 591-601.	7.3	79
167	Multicenter Validation of Association Between Decline in MRIâ€PDFF and Histologic Response in NASH. Hepatology, 2020, 72, 1219-1229.	7.3	79
168	Tremelimumab in Combination With Microwave Ablation in Patients With RefractoryÂBiliary Tract Cancer. Hepatology, 2019, 69, 2048-2060.	7.3	77
169	CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 74, 1145-1154.	3.7	76
170	Longitudinal Assessment of High Blood Pressure in Children with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e112569.	2.5	75
171	Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Experimental Hematology, 2006, 34, 796-801.	0.4	74
172	Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. Journal of Clinical Investigation, 2019, 130, 507-522.	8.2	74
173	Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. Journal of Hepatology, 2022, 76, 1030-1041.	3.7	74
174	Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. British Journal of Haematology, 2004, 124, 777-786.	2.5	73
175	A Novel Bacterium Associated with Lymphadenitis in a Patient with Chronic Granulomatous Disease. PLoS Pathogens, 2006, 2, e28.	4.7	73
176	Digital Necrosis and Disseminated Pneumocystis carinii Infection after Aerosolized Pentamidine Prophylaxis. Annals of Internal Medicine, 1989, 111, 681.	3.9	71
177	Polypoid lesions of airways: early experience with computer-assisted detection by using virtual bronchoscopy and surface curvature Radiology, 1998, 208, 331-337.	7.3	71
178	Melanoma-associated antigen recognized by T cells (MART-1). Cancer, 1999, 87, 37-42.	4.1	71
179	Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology, 2006, 43, 780-787.	7.3	70
180	Identification of microRNAs specifically expressed in hepatitis C virusâ€associated hepatocellular carcinoma. International Journal of Cancer, 2013, 133, 816-824.	5.1	70

#	Article	IF	Citations
181	Automatic classification of white regions in liver biopsies by supervised machine learning. Human Pathology, 2014, 45, 785-792.	2.0	69
182	Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular Carcinoma. Clinical Cancer Research, 2017, 23, 4633-4641.	7.0	68
183	Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthritis Research and Therapy, 2000, 2, 145-53.	3.5	67
184	Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium. Journal of Immunotherapy, 2002, 25, 218-225.	2.4	67
185	Liver injury from nonsteroidal antiâ€inflammatory drugs in the United States. Liver International, 2016, 36, 603-609.	3.9	67
186	The Liver Biopsy in Chronic Hepatitis C: A View from the Other Side of the Microscope. Seminars in Liver Disease, 2005, 25, 52-64.	3.6	66
187	Azathioprine and 6-Mercaptopurine-induced Liver Injury. Journal of Clinical Gastroenterology, 2017, 51, 63-69.	2.2	66
188	Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of NonalcoholicÂSteatohepatitis. Clinical Gastroenterology and Hepatology, 2017, 15, 127-131.e2.	4.4	66
189	Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. Journal of Hepatology, 1994, 21, 1109-1112.	3.7	65
190	Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels. American Journal of Gastroenterology, 2019, 114, 1626-1635.	0.4	65
191	Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 cases. Hepatology, 1995, 22, 1163-1170.	7.3	64
192	Donor genomics influence graft events: The effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. Kidney International, 2004, 66, 1686-1693.	5.2	64
193	Type 1 Diabetes Associated with Acquired Generalized Lipodystrophy and Insulin Resistance: The Effect of Long-Term Leptin Therapy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 26-31.	3.6	64
194	Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clinical Cancer Research, 2017, 23, 2267-2276.	7.0	64
195	Molecular Signature and Mechanisms of Hepatitis D Virus–Associated Hepatocellular Carcinoma. Molecular Cancer Research, 2018, 16, 1406-1419.	3.4	64
196	Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology, 2019, 70, 1841-1855.	7.3	64
197	Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. Biochemistry, 1992, 31, 1665-1672.	2.5	63
198	Prolonged therapy of chronic hepatitis C with ribavirin. Journal of Viral Hepatitis, 1996, 3, 247-252.	2.0	63

#	Article	IF	Citations
199	Pruritus as a presenting symptom of chronic hepatitis C. Digestive Diseases and Sciences, 1998, 43, 2177-2183.	2.3	63
200	Duloxetine hepatotoxicity: a caseâ€series from the drugâ€induced liver injury network. Alimentary Pharmacology and Therapeutics, 2010, 32, 1174-1183.	3.7	63
201	Endemic mycoses in patients with STAT3-mutated hyper-lgE (Job) syndrome. Journal of Allergy and Clinical Immunology, 2015, 136, 1411-1413.e2.	2.9	63
202	Dysfunctional LAD-1 neutrophils and colitis. Gastroenterology, 2001, 121, 958-964.	1.3	62
203	Reactivation of Hepatitis B With Reappearance of Hepatitis B Surface Antigen After Chemotherapy and Immunosuppression. Clinical Gastroenterology and Hepatology, 2009, 7, 1130-1137.	4.4	62
204	Mutations of p53 Gene in Hepatocellular Carcinoma: Roles of Hepatitis B Virus and Aflatoxin Contamination in the Diet. Journal of the National Cancer Institute, 1992, 84, 1638-1641.	6.3	61
205	Pathologic Assessment of Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease, 2007, 11, 17-23.	2.1	61
206	Fibrosis progression in chronic hepatitis C: Morphometric image analysis in the HALT-C trial. Hepatology, 2009, 50, 1738-1749.	7.3	60
207	No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication. Science Advances, 2019, 5, eaav2045.	10.3	60
208	The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut, 2022, 71, 1161-1175.	12.1	60
209	Chemokines and Their Receptors in Human Renal Allotransplantation. Transplantation, 2011, 91, 70-77.	1.0	59
210	Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11369-E11378.	7.1	59
211	Vitamin E treatment in NAFLD patients demonstrates that oxidative stress drives steatosis through upregulation of de-novo lipogenesis. Redox Biology, 2020, 37, 101710.	9.0	58
212	Increased Human Immunodeficiency Virus (HIV) Type 1 DNA Content and Quinolinic Acid Concentration in Brain Tissues from Patients with HIV Encephalopathy. Journal of Infectious Diseases, 1995, 172, 638-647.	4.0	55
213	Late-onset gastrointestinal pain in juvenile dermatomyositis as a manifestation of ischemic ulceration from chronic endarteropathy. Arthritis and Rheumatism, 2007, 57, 881-884.	6.7	55
214	Determination of hepatitis B phenotype using biochemical andÂserological markers. Journal of Viral Hepatitis, 2017, 24, 320-329.	2.0	55
215	Histopathologic changes associated with fialuridine hepatotoxicity. Modern Pathology, 1997, 10, 192-9.	5.5	55
216	Drugâ€induced allergic hepatitis develops in mice when myeloidâ€derived suppressor cells are depleted prior to halothane treatment. Hepatology, 2015, 62, 546-557.	<b>7.</b> 3	54

#	Article	IF	Citations
217	Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology. Journal of Translational Medicine, 2016, 14, 328.	4.4	54
218	Complications of percutaneous liver biopsy with Klatskin needles: a 36â€year singleâ€centre experience. Alimentary Pharmacology and Therapeutics, 2017, 45, 744-753.	3.7	54
219	Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 2318-2326.	7.0	54
220	Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology, 2006, 44, 925-935.	7.3	53
221	Drug-induced Liver Injury. Gastroenterology Clinics of North America, 2017, 46, 273-296.	2.2	53
222	HLAâ€B*35:01 and Green Tea–Induced Liver Injury. Hepatology, 2021, 73, 2484-2493.	7.3	53
223	Cushing's Syndrome Caused by Corticotropin Secretion by Pulmonary Tumorlets. New England Journal of Medicine, 1998, 339, 883-886.	27.0	52
224	Granulomas in the liver. Seminars in Diagnostic Pathology, 2006, 23, 161-169.	1.5	52
225	Gastrointestinal Manifestations of STAT3-Deficient Hyper-IgE Syndrome. Journal of Clinical Immunology, 2017, 37, 695-700.	3.8	52
226	Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance. Science Translational Medicine, 2019, 11, .	12.4	52
227	Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus - associated hepatocellular carcinoma. Journal of Translational Medicine, 2014, 12, 230.	4.4	51
228	Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists. Gastroenterology, 2015, 149, 1305-1308.	1.3	51
229	Mesothelin as a Potential Therapeutic Target in Human Cholangiocarcinoma. Journal of Cancer, 2010, 1, 141-149.	2.5	50
230	Update on Fatty Liver Disease and Steatohepatitis. Advances in Anatomic Pathology, 2011, 18, 294-300.	4.3	50
231	Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1375-1380.	7.1	50
232	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 367-378.	2.0	50
233	Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV,the, 2019, 6, e821-e830.	4.7	50
234	FGF21 underlies a hormetic response to metabolic stress in methylmalonic acidemia. JCI Insight, 2018, 3,	5.0	50

#	Article	IF	Citations
235	Histological classification of liver and intrahepatic bile duct cancers in SEER registries. Journal of Registry Management, 2011, 38, 201-5.	0.1	50
236	Quantitative Analysis of Viral Burden in Tissues from Adults and Children with Symptomatic Human Immunodeficiency Virus Type 1 Infection Assessed by Polymerase Chain Reaction. Journal of Infectious Diseases, 1994, 170, 325-333.	4.0	49
237	Identification and Characterization of Fenofibrate-Induced Liver Injury. Digestive Diseases and Sciences, 2017, 62, 3596-3604.	2.3	49
238	Expanding the phenotype of COPA syndrome: a kindred with typical and atypical features. Journal of Medical Genetics, 2019, 56, 778-782.	3.2	49
239	Progression of Fatty Liver Disease in Children Receiving Standard of Care Lifestyle Advice. Gastroenterology, 2020, 159, 1731-1751.e10.	1.3	49
240	<scp>NASH</scp> resolution is associated with improvements in <scp>HDL</scp> and triglyceride levels but not improvement in <scp>LDL</scp> or nonâ€ <scp>HDL</scp> levels. Alimentary Pharmacology and Therapeutics, 2015, 41, 301-309.	3.7	48
241	Acute Liver Injury due to Flavocoxid (Limbrel), a Medical Food for Osteoarthritis. Annals of Internal Medicine, 2012, 156, 857.	3.9	47
242	Hydrogen-1 MR Spectroscopy for Measurement and Diagnosis of Hepatic Steatosis. American Journal of Roentgenology, 2012, 199, 2-7.	2.2	46
243	Liver Regeneration Signature in Hepatitis B Virus (HBV)-Associated Acute Liver Failure Identified by Gene Expression Profiling. PLoS ONE, 2012, 7, e49611.	2.5	46
244	Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease With Severe Consequences. Frontiers in Immunology, 2018, 9, 1361.	4.8	46
245	Consensus recommendations for histological criteria of autoimmune hepatitis from the International <scp>AIH</scp> Pathology Group. Liver International, 2022, 42, 1058-1069.	3.9	45
246	Necropsy as a research method in the age of molecular pathology. Lancet, The, 1995, 346, 945-948.	13.7	44
247	Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations. Journal of Clinical Oncology, 2001, 19, 2754-2763.	1.6	44
248	Longâ€term outcome of chronic hepatitis <scp>C</scp> after sustained virological response to interferonâ€based therapy. Alimentary Pharmacology and Therapeutics, 2013, 37, 887-894.	3.7	44
249	Liver injury is associated with mortality in sickle cell disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 912-921.	3.7	44
250	Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage. Cancer Immunology Research, 2015, 3, 557-566.	3.4	44
251	Noninvasive markers for staging fibrosis in chronic delta hepatitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 127-138.	3.7	44
252	Lung Manifestations in an Autopsy-Based Series of Pulmonary or Disseminated Nontuberculous Mycobacterial Disease. Chest, 2012, 141, 1203-1209.	0.8	43

#	Article	IF	Citations
253	Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Alimentary Pharmacology and Therapeutics, 2019, 49, 1195-1204.	3.7	43
254	Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e520-e533.	3.6	43
255	NASH and cryptogenic cirrhosis: a histological analysis. Annals of Hepatology, 2009, 8, 346-52.	1.5	43
256	Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers. Journal of Viral Hepatitis, 2001, 8, 256-263.	2.0	42
257	Hepatic Pathology among Patients without Known Liver Disease Undergoing Bariatric Surgery: Observations and a Perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study. Seminars in Liver Disease, 2014, 34, 098-107.	3.6	42
258	Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. Aids, 2015, 29, 2297-2302.	2.2	42
259	Under-reporting and Poor Adherence to Monitoring Guidelines for Severe Cases of Isoniazid Hepatotoxicity. Clinical Gastroenterology and Hepatology, 2015, 13, 1676-1682.e1.	4.4	42
260	Identification and Characterization of Cefazolin-Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2015, 13, 1328-1336.e2.	4.4	42
261	Effects of Metreleptin in Pediatric Patients With Lipodystrophy. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1511-1519.	3.6	42
262	Placebo in Nonalcoholic Steatohepatitis: Insight Into Natural History and Implications for Future Clinical Trials. Clinical Gastroenterology and Hepatology, 2008, 6, 1243-1248.	4.4	40
263	The influence of DNA repair on neurological degeneration, cachexia, skin cancer and internal neoplasms: autopsy report of four xeroderma pigmentosum patients (XP-A, XP-C and XP-D). Acta Neuropathologica Communications, 2013, 1, 4.	5.2	40
264	The Spectrum of Hepatic Involvement in Patients With Telomere Disease. Hepatology, 2019, 69, 2579-2585.	7.3	40
265	CT and MRI of Hepatic Abscess in Patients with Chronic Granulomatous Disease. American Journal of Roentgenology, 2006, 187, 482-490.	2.2	39
266	Sarcoidosis in Chronic Granulomatous Disease. Pediatrics, 2006, 117, e590-e595.	2.1	39
267	Cutaneous sarcoidosis and primary biliary cirrhosis: A chance association or related diseases?. Journal of the American Academy of Dermatology, 2008, 58, 326-335.	1.2	39
268	The histopathological evaluation of drugâ€induced liver injury. Histopathology, 2017, 70, 81-93.	2.9	38
269	17â∈Beta Hydroxysteroid Dehydrogenase 13 Deficiency Does Not Protect Mice From Obesogenic Diet Injury. Hepatology, 2021, 73, 1701-1716.	7.3	38
270	Fibrosis Progression in African Americans and Caucasian Americans With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2008, 6, 1403-1411.	4.4	37

#	Article	IF	Citations
271	Recombinant Human Factor VIIa for Alveolar Hemorrhage Following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 969-978.	2.0	37
272	Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Digestive Diseases and Sciences, 2016, 61, 2741-2748.	2.3	37
273	Hepatic Manifestations of Cystic Fibrosis. Clinics in Liver Disease, 2019, 23, 263-277.	2.1	37
274	Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD. Annals of Diagnostic Pathology, 2020, 47, 151518.	1.3	37
275	Nodular Regenerative Hyperplasia and Severe Portal Hypertension in Cystinosis. Clinical Gastroenterology and Hepatology, 2006, 4, 387-394.	4.4	36
276	A phase II study of TRC105Âin patients with hepatocellular carcinoma who have progressed on sorafenib. United European Gastroenterology Journal, 2015, 3, 453-461.	3.8	36
277	MKS3-Related Ciliopathy with Features of Autosomal Recessive Polycystic Kidney Disease, Nephronophthisis, and Joubert Syndrome. Journal of Pediatrics, 2009, 155, 386-392.e1.	1.8	35
278	Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes and Control, 2009, 20, 361-368.	1.8	35
279	Caspase-8 Deficiency Presenting as Late-Onset Multi-Organ Lymphocytic Infiltration with Granulomas in two Adult Siblings. Journal of Clinical Immunology, 2015, 35, 348-355.	3.8	35
280	Hepatitis B Surface Antigen Activates Unfolded Protein Response in Forming Ground Glass Hepatocytes of Chronic Hepatitis B. Viruses, 2019, 11, 386.	3.3	35
281	Histopathological challenges in suspected drugâ€induced liver injury. Liver International, 2018, 38, 198-209.	3.9	34
282	Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clinical Gastroenterology and Hepatology, 2022, 20, 256-268.	4.4	34
283	Improvement in Liver Histology Is Associated With Reduction in Dyslipidemia in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 360-367.	1.8	33
284	Automatic quantification of lobular inflammation and hepatocyte ballooning in nonalcoholic fatty liver disease liver biopsies. Human Pathology, 2015, 46, 767-775.	2.0	33
285	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. American Journal of Gastroenterology, 2019, 114, 746-757.	0.4	33
286	Hepatic Gene Networks in Morbidly Obese Patients With Nonalcoholic Fatty Liver Disease. Obesity Surgery, 2010, 20, 1698-1709.	2.1	32
287	Rate of Progression of Hepatic Fibrosis in Patients With Chronic Hepatitis C: Results From the HALT-C Trial. Gastroenterology, 2011, 141, 900-908.e2.	1.3	32
288	The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. Journal of Hepatology, 2018, 69, 1317-1325.	3.7	32

#	Article	IF	Citations
289	RB tumor suppressor gene expression in hepatocellular carcinomas from patients infected with the hepatitis B virus. Journal of Medical Virology, 1994, 44, 67-73.	5.0	31
290	Vemurafenibâ€induced granulomatous hepatitis. Hepatology, 2017, 65, 745-748.	7.3	31
291	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, e349-e360.	2.3	31
292	Liver-Resident Bystander CD8+ TÂCells Contribute to Liver Disease Pathogenesis in Chronic Hepatitis D Virus Infection. Gastroenterology, 2021, 161, 1567-1583.e9.	1.3	31
293	The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis. American Journal of Clinical Pathology, 2015, 144, 601-606.	0.7	30
294	Misuse of scoring systems. Hepatology, 2011, 54, 369-370.	7.3	29
295	Discordance Among Transient Elastography, Aspartate Aminotransferase to Platelet Ratio Index, and Histologic Assessments of Liver Fibrosis in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2013, 11, 303-308.e1.	4.4	29
296	Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology, 2015, 62, 1364-1374.	7.3	29
297	Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease. BioMed Research International, 2017, 2017, 1-8.	1.9	29
298	4-HNE Immunohistochemistry and Image Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E Treatment in NAFLD as a Proof of Concept. Journal of Histochemistry and Cytochemistry, 2020, 68, 635-643.	2.5	29
299	Regulation of Matrix Metalloproteinases during Extracellular Matrix Turnover. Advances in Experimental Medicine and Biology, 1995, 385, 151-159.	1.6	29
300	A 25-Year Study of the Clinical and Histologic Outcomes of Hepatitis C Virus Infection and Its Modes of Transmission in a Cohort of Initially Asymptomatic Blood Donors. Journal of Infectious Diseases, 2012, 206, 654-661.	4.0	28
301	Association Between Severe Serum Alanine Aminotransferase Flares and Hepatitis B e Antigen Seroconversion and HBV DNA Decrease in Untreated Patients With Chronic HBV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 2541-2551.e2.	4.4	28
302	Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy. Neurology, 2017, 89, 2481-2490.	1.1	27
303	Standardising the interpretation of liver biopsies in nonâ€alcoholic fatty liver disease clinical trials. Alimentary Pharmacology and Therapeutics, 2019, 50, 1100-1111.	3.7	27
304	Vibrationâ€controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. Journal of Viral Hepatitis, 2020, 27, 428-436.	2.0	27
305	Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity. Digestive Diseases and Sciences, 2013, 58, 1766-1775.	2.3	26
306	Liver histology in the diagnosis and prognosis of drug-induced liver injury. Clinical Liver Disease, 2014, 4, 12-16.	2.1	26

#	Article	IF	CITATIONS
307	A new cause of Zollinger–Ellison syndrome: Non–Small cell lung cancer. Gastroenterology, 2001, 120, 1271-1278.	1.3	25
308	Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia, 2004, 10, 413-421.	2.1	25
309	Severe Hepatocellular Injury With Apoptosis Induced by a Hepatitis C Polymerase Inhibitor. Journal of Clinical Gastroenterology, 2009, 43, 374-381.	2.2	25
310	Clinical and Histological Features of Idiosyncratic Acute Liver Injury Caused by Temozolomide. Digestive Diseases and Sciences, 2013, 58, 1415-1421.	2.3	25
311	APECEDâ€Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort. Hepatology, 2021, 73, 1088-1104.	7.3	25
312	Perirenal myelolipoma. Urology, 1997, 49, 128-130.	1.0	24
313	Loss of heterozygosity in P53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior. Human Pathology, 2000, 31, 233-238.	2.0	24
314	Human germline hedgehog pathway mutations predispose to fatty liver. Journal of Hepatology, 2017, 67, 809-817.	3.7	24
315	Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease. Journal of Pediatrics, 2018, 198, 76-83.e2.	1.8	24
316	Relationship between resolution of nonâ€alcoholic steatohepatitis and changes in lipoprotein subâ€fractions: a postâ€hoc analysis of the <scp>PIVENS</scp> trial. Alimentary Pharmacology and Therapeutics, 2019, 49, 1205-1213.	3.7	24
317	Progelatinase A mRNA Expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology, 1997, 50, 295-301.	1.0	23
318	Association of Interleukinâ€15–Induced Peripheral Immune Activation with Hepatic Stellate Cell Activation in Persons Coinfected with Hepatitis C Virus and HIV. Journal of Infectious Diseases, 2009, 200, 619-623.	4.0	23
319	Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Alimentary Pharmacology and Therapeutics, 2016, 44, 1253-1264.	3.7	23
320	Recent Advances in the Histopathology of Drug-Induced Liver Injury. Surgical Pathology Clinics, 2018, 11, 297-311.	1.7	23
321	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Coâ€infected Adults. Hepatology, 2020, 71, 411-421.	7.3	23
322	Liver Histology. Clinics in Liver Disease, 2020, 24, 61-74.	2.1	23
323	Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology, 2021, 73, 2124-2140.	7.3	23
324	Risk factors for positive minor salivary gland biopsy findings in Sj $\tilde{A}$ ¶gren's syndrome and dry mouth patients. Arthritis and Rheumatism, 2002, 47, 189-195.	6.7	22

#	Article	IF	CITATIONS
325	GIMAP5 maintains liver endothelial cell homeostasis and prevents portal hypertension. Journal of Experimental Medicine, 2021, 218, .	8.5	22
326	A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma. Oncologist, 2022, 27, e273-e285.	3.7	22
327	A Novel Case of Bisphosphonate-Related Osteonecrosis of the Torus Palatinus in a Patient with Metastatic Breast Cancer. Oncology, 2006, 71, 306-308.	1.9	21
328	Factors associated with the platelet count in patients with chronic hepatitis C. Thrombosis Research, 2015, 135, 823-828.	1.7	21
329	Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterology, 2016, 3, e000114.	2.7	21
330	Relationship Between Metabolic Syndrome, Alanine Aminotransferase Levels, and Liver Disease Severity in a Multiethnic North American Cohort With Chronic Hepatitis B. Diabetes Care, 2018, 41, 1251-1259.	8.6	21
331	Antimicrobials and Antiepileptics Are the Leading Causes of Idiosyncratic Drugâ€induced Liver Injury in American Children. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, 152-159.	1.8	21
332	The Delta-4 fibrosis score (D4FS): A novel fibrosis score in chronic hepatitis D. Antiviral Research, 2020, 174, 104691.	4.1	21
333	Value of liver biopsy in the diagnosis of drug-induced liver injury. Journal of Hepatology, 2022, 76, 1070-1078.	3.7	21
334	Expression in Transgenic Mice of Dominant Interfering Fas Mutations: A Model for Human Autoimmune Lymphoproliferative Syndrome. Clinical Immunology, 1999, 93, 34-45.	3.2	20
335	CD40 agonist antibody mediated improvement of chronic Cryptosporidium infection in patients with X-linked hyper IgM syndrome. Clinical Immunology, 2012, 143, 152-161.	3.2	20
336	Adverse effects of antiretroviral therapy on liver hepatocytes and endothelium in HIV patients: An ultrastructural perspective. Ultrastructural Pathology, 2017, 41, 186-195.	0.9	20
337	Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B. American Journal of Gastroenterology, 2021, 116, 1686-1697.	0.4	20
338	Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?. American Journal of Gastroenterology, 2021, 116, 206-209.	0.4	20
339	Validation of the accuracy of the FASTâ,,¢ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms. PLoS ONE, 2022, 17, e0266859.	2.5	20
340	Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis <scp>B</scp> . Alimentary Pharmacology and Therapeutics, 2012, 35, 1027-1035.	3.7	19
341	A pilot study of AMP-224, a PD-L2 Fc fusion protein, in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2016, 34, 560-560.	1.6	19
342	Histopathology, grading and staging of nonalcoholic fatty liver disease. Minerva Gastroenterology, 2017, 64, 28-38.	0.5	19

#	Article	IF	CITATIONS
343	Prevention and regression of megamitochondria and steatosis by blocking mitochondrial fusion in the liver. IScience, 2022, 25, 103996.	4.1	19
344	Associations of gender and a proxy of female menopausal status with histological features of drugâ€induced liver injury. Liver International, 2017, 37, 1723-1730.	3.9	18
345	Chitinase 3-like $1$ is a profibrogenic factor overexpressed in the aging liver and in patients with liver cirrhosis. Proceedings of the National Academy of Sciences of the United States of America, 2021, $118$ , .	7.1	18
346	Age, race and viral genotype are associated with the prevalence of hepatitis B e antigen in children and adults with chronic hepatitis B. Journal of Viral Hepatitis, 2019, 26, 856-865.	2.0	17
347	Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. Liver International, 2021, 41, 1884-1893.	3.9	17
348	Haploidentical related donor hematopoietic stem cell transplantation withÂpost-transplantation cyclophosphamide for DOCK8 deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 1239-1242.e1.	3.8	16
349	A Pilot Genomeâ€Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH. Hepatology Communications, 2019, 3, 1571-1584.	4.3	16
350	Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis. Liver International, 2021, 41, 996-1011.	3.9	16
351	Durable virological response and functional cure of chronic hepatitis D after longâ€term peginterferon therapy. Alimentary Pharmacology and Therapeutics, 2021, 54, 176-182.	3.7	16
352	Clinical characteristics of antiepileptic-induced liver injury in patients from the DILIN prospective study. Journal of Hepatology, 2022, 76, 832-840.	3.7	16
353	Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection. AIDS Research and Human Retroviruses, 2015, 31, 961-966.	1.1	15
354	Hepatocellular carcinoma: Liver biopsy in the balance. Hepatology, 2018, 68, 13-15.	7.3	15
355	Sclerosing Cholangitis–Like Changes on Magnetic Resonance Cholangiography in Patients With Drug Induced Liver Injury. Clinical Gastroenterology and Hepatology, 2019, 17, 789-790.	4.4	15
356	The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 764-775.	2.8	15
357	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. Clinical Infectious Diseases, 2021, 73, e3275-e3285.	5.8	15
358	Clinical Predictors of Liver Fibrosis Presence and Progression in Human Immunodeficiency Virus–Associated Nonalcoholic Fatty Liver Disease. Clinical Infectious Diseases, 2021, 72, 2087-2094.	5.8	15
359	Highly multiplexed 2-dimensional imaging mass cytometry analysis of HBV-infected liver. JCI Insight, 2021, 6, .	5.0	15
360	A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2015, 33, 4081-4081.	1.6	15

#	Article	IF	CITATIONS
361	Vanishing bile duct syndrome in human immunodeficiency virus infected adults: A report of two cases. World Journal of Gastroenterology, 2013, 19, 115.	3.3	15
362	Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. Hepatology, 2022, 76, 1150-1163.	7.3	15
363	Evidence of SARS-CoV-2-Specific T-Cell-Mediated Myocarditis in a MIS-A Case. Frontiers in Immunology, 2021, 12, 779026.	4.8	15
364	The association of mast cells and serotonin in children with chronic abdominal pain of unknown etiology. BMC Research Notes, 2010, 3, 265.	1.4	14
365	Liver stiffness increases acutely during sickle cell vasoâ€occlusive crisis. American Journal of Hematology, 2013, 88, E250-4.	4.1	14
366	Challenges in the hepatic histopathology in non-alcoholic fatty liver disease. Gut, 2017, 66, 1539-1540.	12.1	14
367	The effect of a phase transition on penetration of phospholipid monolayers by melittin and glucagon. Archives of Biochemistry and Biophysics, 1983, 227, 242-247.	3.0	13
368	Hepatic injury due to drugs, herbal compounds, chemicals and toxins., 2012,, 645-760.		13
369	Drugs and Toxins. , 2018, , 673-779.		13
370	Bacterial Translocation and Host Immune Activation in Chronic Hepatitis C Infection. Open Forum Infectious Diseases, 2019, 6, .	0.9	13
371	Garcinia cambogia, Either Alone or in Combination With Green Tea, Causes Moderate to Severe Liver Injury. Clinical Gastroenterology and Hepatology, 2022, 20, e1416-e1425.	4.4	13
372	Postbariatric hypoglycemia: symptom patterns and associated risk factors in the Longitudinal Assessment of Bariatric Surgery study. Surgery for Obesity and Related Diseases, 2021, 17, 1787-1798.	1.2	13
373	Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight, 2020, 5, .	5.0	13
374	Primary sarcoma of the heart causing mitral stenosis. American Journal of Cardiology, 1990, 66, 893-895.	1.6	12
375	Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B*1. Hepatology, 1995, 22, 1021-1026.	7.3	12
376	Portal Pressure in Noncirrhotic Portal Hypertension: To Measure or Not to Measure. Hepatology, 2019, 70, 2228-2230.	7.3	12
377	State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials—A Multidisciplinary Approach. Journal of Clinical Oncology, 2020, 38, 1633-1640.	1.6	12
378	Characterization of Gut Microbiome in Liver Transplant Recipients With Nonalcoholic Steatohepatitis. Transplantation Direct, 2020, 6, e625.	1.6	12

#	Article	IF	CITATIONS
379	Surgical transplant physical examination: Correlation of renal resistance index and biopsy-proven chronic allograft nephropathy. Journal of the American College of Surgeons, 2005, 200, 552-556.	0.5	11
380	Myxovirus-1 and protein kinase haplotypes and fibrosis in chronic hepatitis C virus. Hepatology, 2007, 46, 74-83.	7.3	11
381	Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. Aids, 2008, 22, 1433-1439.	2.2	11
382	Probabilistic (Bayesian) Modeling of Gene Expression in Transplant Glomerulopathy. Journal of Molecular Diagnostics, 2010, 12, 653-663.	2.8	11
383	Inverse relationship of interleukin-6 and mast cells in children with inflammatory and non-inflammatory abdominal pain phenotypes. World Journal of Gastrointestinal Pathophysiology, 2012, 3, 102.	1.0	11
384	Clinical and Histopathologic Features of Interstitial Lung Disease in Erdheim–Chester Disease. Journal of Clinical Medicine, 2018, 7, 243.	2.4	11
385	Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, 157, 1448-1456.e1.	1.3	11
386	Precore and Basal Core Promoter Hepatitis B Virus (HBV) Variants Are Present From a Young Age and Differ Across HBV Genotypes. Hepatology, 2021, 73, 1637-1651.	7.3	11
387	Clinical and Genetic Risk Factors of Recurrent Nonalcoholic Fatty Liver Disease After Liver Transplantation. Clinical and Translational Gastroenterology, 2021, 12, e00302.	2.5	11
388	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBVâ€HIV Coâ€infected Adults in North America. Hepatology, 2021, 74, 1174-1189.	7.3	11
389	Compartmental analysis of plasma and liver n-3 essential fatty acids in alcohol-dependent men during withdrawal. Journal of Lipid Research, 2009, 50, 154-161.	4.2	10
390	Evaluation of tacrolimus abbreviated areaâ€underâ€theâ€curve monitoring in renal transplant patients who are potientially at risk for adverse events. Clinical Transplantation, 2010, 24, 557-563.	1.6	10
391	The Alcoholic Hepatitis Histologic Score: Structured Prognostic BiopsyÂEvaluation Comes to Alcoholic Hepatitis. Gastroenterology, 2014, 146, 1156-1158.	1.3	10
392	Noncirrhotic portal hypertension: Pathology and nomenclature. Clinical Liver Disease, 2015, 5, 123-126.	2.1	10
393	Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology Communications, 2017, 1, 288-292.	4.3	10
394	The corticosteroid compounds prednisolone and vamorolone do not alter the nociception phenotype and exacerbate liver injury in sickle cell mice. Scientific Reports, 2018, 8, 6081.	3.3	10
395	Spleen and Liver Volumetrics as Surrogate Markers of Hepatic Venous Pressure Gradient in Patients With Noncirrhotic Portal Hypertension. Hepatology Communications, 2018, 2, 923-932.	4.3	10
396	In Utero Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 769-771.	1.3	10

#	Article	IF	CITATIONS
397	Tubular Epithelial and Peritubular Capillary Endothelial Injury in COVID-19 AKI. Kidney International Reports, 2021, 6, 518-525.	0.8	10
398	Telomere Length and Survival of Patients with Hepatocellular Carcinoma in the United States. PLoS ONE, 2016, 11, e0166828.	2.5	10
399	Bayesian ROC curve estimation under verification bias. Statistics in Medicine, 2014, 33, 5081-5096.	1.6	9
400	Utilization of HPASubC for the Identification of Sinusoid-Specific Proteins in the Liver. Journal of Proteome Research, 2016, 15, 1623-1629.	3.7	9
401	Long-Term Changes in Hepatic Fibrosis following Hepatitis C Viral Clearance in Patients with and without HIV. Antiviral Therapy, 2019, 24, 451-457.	1.0	9
402	Tandem Orthotopic Living Donor Liver Transplantation Followed by Same Donor Haploidentical Hematopoietic Stem Cell Transplantation for DOCK8 Deficiency. Transplantation, 2019, 103, 2144-2149.	1.0	9
403	Zymography, Casein Zymography, and Reverse Zymography: Activity Assays for Proteases and their Inhibitors., 1999,, 63-76.		9
404	Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease ( <scp>NAFLD</scp> ). Alimentary Pharmacology and Therapeutics, 2022, 55, 1441-1451.	3.7	9
405	Expression of transforming growth factor alpha in the liver before and after interferon alfa therapy for chronic hepatitis B. Hepatology, 1995, 22, 1021-1026.	7.3	8
406	Pilot study of pioglitazone in nonalcoholic steatohepatitis. Gastroenterology, 2003, 124, A708.	1.3	8
407	Rapid Development of Advanced Liver Fibrosis after Acquisition of Hepatitis C Infection during Primary HIV Infection. AIDS Patient Care and STDs, 2009, 23, 403-406.	2.5	8
408	Host Genetics, Steatosis and Insulin Resistance among African Americans and Caucasian Americans with Hepatitis C Virus Genotype-1 Infection. Intervirology, 2009, 52, 49-56.	2.8	8
409	Trials of obeticholic acid for non-alcoholic steatohepatitis – Authors' reply. Lancet, The, 2015, 386, 28-29.	13.7	8
410	On beyond staging and grading: Liver biopsy evaluation in a posttreatment world. Hepatology, 2017, 65, 1432-1434.	7.3	8
411	Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for nonâ€alcoholic fatty liver disease. Liver International, 2018, 38, 797-802.	3.9	8
412	Pulmonary tumor thrombotic microangiopathy and pulmonary veno-occlusive disease in a woman with cervical cancer treated with cediranib and durvalumab. BMC Pulmonary Medicine, 2018, 18, 112.	2.0	8
413	The Clinical Spectrum and Diagnosis of Oxaliplatin Liver Injury in the Era of Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 2199-2201.	4.4	8
414	Platelet count as a screening tool for compensated cirrhosis in chronic viral hepatitis. World Journal of Gastrointestinal Pathophysiology, 2021, 12, 40-50.	1.0	8

#	Article	IF	CITATIONS
415	Nodular regenerative hyperplasia in X-linked agammaglobulinemia: An underestimated and severe complication. Journal of Allergy and Clinical Immunology, 2022, 149, 400-409.e3.	2.9	8
416	Hepatocellular carcinoma as a complication of Niemannâ€Pick disease type C1. American Journal of Medical Genetics, Part A, 2021, 185, 3111-3117.	1.2	8
417	Nonalcoholic fatty liver disease risk and histologic severity are associated with genetic polymorphisms in children. Hepatology, 2023, 77, 197-212.	7.3	8
418	Hepatoportal venopathy due to disseminated Mycobacterium avium complex infection in a child with IFN- $\hat{l}^3$ receptor 2 deficiency. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 95-100.	2.8	7
419	Growth Hormone Releasing Hormone Reduces Circulating Markers of Immune Activation in Parallel with Effects on Hepatic Immune Pathways in Individuals with HIV-infection and Nonalcoholic Fatty Liver Disease. Clinical Infectious Diseases, 2021, 73, 621-630.	5.8	7
420	Changes in serum hepatitis B surface and e antigen, interferonâ€inducible protein 10, and aminotransferase levels during combination therapy of immuneâ€tolerant chronic hepatitis B. Hepatology, 2022, 76, 775-787.	7.3	7
421	Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells. Frontiers in Immunology, 2021, 12, 801281.	4.8	7
422	Case Series: Biliary Leak After Transjugular Liver Biopsy. American Journal of Gastroenterology, 2013, 108, 145-147.	0.4	6
423	Ataxia telangiectasia associated with nodular regenerative hyperplasia. Journal of Clinical Immunology, 2016, 36, 739-742.	3.8	6
424	Microvascular inflammation in renal allograft biopsies assessed by endothelial and leukocyte coâ€immunostain: a retrospective study on reproducibility and clinical/prognostic correlates. Transplant International, 2018, 32, 300-312.	1.6	6
425	Vibration Controlled Transient Elastography (Fibroscan®) in sickle cell liver disease ―could we strike while the liver is hard?. British Journal of Haematology, 2019, 187, 117-123.	2.5	6
426	Hepatic Histology in Treatmentâ€naà ve Children With Chronic Hepatitis B Infection Living in the United States and Canada. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 99-105.	1.8	6
427	Role of Hepatitis E Virus Infection in North American Patients With Severe Acute Liver Injury. Clinical and Translational Gastroenterology, 2020, 11, e00273.	2.5	6
428	Cryptosporidium infection in dedicator of cytokinesis 8 (DOCK 8) deficiency. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3663-3666.e1.	3.8	6
429	HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 2022, 20, e890-e894.	4.4	6
430	Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach. Scientific Reports, 2021, 11, 10485.	3.3	6
431	Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. Journal of Viral Hepatitis, 2021, 28, 1526-1538.	2.0	6
432	Primary Biliary Cirrhosis Overlapping with Autoimmune Hepatitis in an HIV-Infected Patient on Antiretroviral Therapy. Journal of Interdisciplinary Histopathology, 2013, 1, 270.	0.2	6

#	Article	IF	Citations
433	Application of NIDDK nash pathologic protocol to patients with non-alcoholic fatty liver disease. Gastroenterology, 2000, 118, A974.	1.3	5
434	Hepatic Histologic Response (HR) to Combination Therapy among HCV/HIV-Coinfected Individuals: Interferon Induces HR Independent of Sustained Virologic Response (SVR). AIDS Research and Human Retroviruses, 2006, 22, 1091-1098.	1.1	5
435	GI involvement in disseminated Mycobacterium genavense: endoscopy and histology. Gastrointestinal Endoscopy, 2011, 74, 688-690.	1.0	5
436	HIV Through the Looking Glass. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 123-127.	2.1	5
437	Bone marrow failure and extramedullary hematopoiesis in McCune-Albright syndrome. Osteoporosis International, 2018, 29, 237-241.	3.1	5
438	Intrahepatic cholangiocarcinoma as a rare secondary malignancy after allogeneic hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: A case report. Pediatric Transplantation, 2020, 24, e13653.	1.0	5
439	Liver Biopsy Shines a Light on COVID-19-Related Liver Injury. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 881-882.	4.5	5
440	Clinical significance of quantitative e antigen in a cohort of hepatitis B virusâ€infected children and adults in North America. Journal of Viral Hepatitis, 2021, 28, 1042-1056.	2.0	5
441	Melanomaâ€associated antigen recognized by T cells (MARTâ€1). Cancer, 1999, 87, 37-42.	4.1	5
442	Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis. Pediatric Rheumatology, 2022, 20, 30.	2.1	5
443	Incidence of Type 2 Diabetes in Children With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2023, 21, 1261-1270.	4.4	5
444	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 1845-1846.	4.4	4
445	Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. , 2016, , 223-247.		4
446	Exploring the Link Between Platelet Numbers and Vascular Homeostasis Across Early and Late Stages of Fibrosis in Hepatitis C. Digestive Diseases and Sciences, 2020, 65, 524-533.	2.3	4
447	Analysis of <scp><i>TP53</i></scp> aflatoxin signature mutation in hepatocellular carcinomas from Guatemala: A crossâ€sectional study (2016â€2017). Health Science Reports, 2020, 3, e155.	1.5	4
448	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV–HIV Co-infected Adults. Digestive Diseases and Sciences, 2022, 67, 676-688.	2.3	4
449	Imaging, Pathology, and Immune Correlates in the Woodchuck Hepatic Tumor Model. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 71-83.	3.7	4
450	Tip of the iceberg: A comprehensive review of liver disease in Inborn errors of immunity. Hepatology, 2022, 76, 1845-1861.	7.3	4

#	Article	IF	Citations
451	Histopathological Evaluation of Drug-Induced Liver Disease. , 2013, , 241-263.		3
452	Plasma Osteopontin Is a Biomarker Specifically Associated with Bronchiolitis Obliterans Syndrome after HCT. Biology of Blood and Marrow Transplantation, 2016, 22, S417-S418.	2.0	3
453	Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years. Antiviral Research, 2019, 168, 61-67.	4.1	3
454	Platelet-derived growth factor receptor-alpha-positive myeloid neoplasm presenting as eosinophilic gastrointestinal disease. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2089-2091.	3.8	3
455	Recurrent Nodular Regenerative Hyperplasia Following Liver Transplantation in Common Variable Immunodeficiency. Hepatology, 2021, 74, 1698-1701.	7.3	3
456	Microbial Translocation in the Context of Hepatitis B Infection and Hepatitis D Infection. Open Forum Infectious Diseases, 2021, 8, ofaa496.	0.9	3
457	Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis. Clinical Chemistry, 1997, 43, 1952-7.	3.2	3
458	Fazarabine. American Journal of Clinical Oncology: Cancer Clinical Trials, 1993, 16, 34-37.	1.3	2
459	An unusual presentation of perinatally transmitted hepatitis C. Archives of Disease in Childhood, 2003, 88, 160-161.	1.9	2
460	The role of the hepatopathologist in the assessment of drugâ€induced liver injury. Clinical Liver Disease, 2017, 9, 34-37.	2.1	2
461	The first malignant primary hepatic glomus tumor: A case report. International Journal of Surgery Case Reports, 2020, 70, 197-200.	0.6	2
462	Abstract A195: Tremelimimab activates CD4 and CD8+ T cells in patients with hepatocellular carcinoma. , 2016, , .		2
463	Abnormal liver tests are not sufficient for diagnosis of hepatic graftâ€versusâ€host disease in critically ill patients. Hepatology Communications, 2022, 6, 2210-2220.	4.3	2
464	Effect of inhibition of ornithine decarboxylase activity in a model of acute hepatocellular necrosis. European Journal of Gastroenterology and Hepatology, 1998, 10, 503-508.	1.6	1
465	E1 therapeutic vaccination for chronic hepatitis C: All that glitters is not gold. Hepatology, 2003, 38, 1092-1094.	7.3	1
466	Immunologic monitoring of the transplant recipient: challenges and approaches with antibody induction. Transplantation Reviews, 2003, 17, S20-S25.	2.9	1
467	Mechanism of action of metformin in nonalcoholic steatohepatitis: authors' reply. Alimentary Pharmacology and Therapeutics, 2009, 29, 603-604.	3.7	1
468	Pattern of Hepatitis B Virus (HBV) Core Antigen (HB CAG +) and Surface Antigen (HBSAG) Staining in Patients Co-Infected with Human Immunodeficiency Virus (HIV). Gastroenterology, 2017, 152, S1070.	1.3	1

#	Article	IF	Citations
469	Three variants in the nicotinamide adenine dinucleotide phosphate oxidase complex are associated with HCVâ€related liver damage. Hepatology Communications, 2017, 1, 973-982.	4.3	1
470	Mounier-Kuhn Syndrome Mimicking Lymphangioleiomyomatosis. Chest, 2018, 153, e19-e23.	0.8	1
471	Drug-Induced Liver Injury: Understanding the Different Immune-Mediated Phenotypes and Clinical Management. Current Hepatology Reports, 2018, 17, 235-244.	0.9	1
472	Liver Injury Due to Drugs and Herbal Agents. , 2018, , 327-370.		1
473	The Role of Liver Biopsy in Drug-Induced Liver Injury. Current Hepatology Reports, 2019, 18, 287-293.	0.9	1
474	Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma. Clinical Lung Cancer, 2020, 21, e25-e29.	2.6	1
475	Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B. GastroHep, 2021, 3, 196-208.	0.6	1
476	Unhealthy Eating, Psychopathology, and Nonalcoholic Fatty Liver Disease in Youth Presenting for Bariatric Surgery. Journal of Pediatric Gastroenterology and Nutrition, 2021, 73, 670-676.	1.8	1
477	A pilot study of immune checkpoint inhibition (tremelimumab and/or MEDI4736) in combination with radiation therapy in patients with unresectable pancreatic cancer Journal of Clinical Oncology, 2016, 34, TPS470-TPS470.	1.6	1
478	Acute Hepatocellular Injury With Autoimmune Features Associated With Move Free® Dietary Supplement. American Journal of Gastroenterology, 2015, 110, S330.	0.4	1
479	Solid organ transplantation at the National Institutes of Health: development of a research-based transplantation practice. Clinical Transplants, 2005, , 131-44.	0.2	1
480	Safety of liver biopsy in patients with sickle cell related liver disease: A singleâ€center experience. American Journal of Hematology, 2022, 97, .	4.1	1
481	Phenotypic Features of Cystic Lung Disease in Proteus Syndrome: A Clinical Trial. Annals of the American Thoracic Society, 2022, 19, 1871-1880.	3.2	1
482	6 Pathology of hepatitis C. Biomedical Research Reports, 2000, , 107-III.	0.3	0
483	CORRELATION OF RENAL RESISTANCE INDEX AND BIOPSY PROVEN CHRONIC ALLOGRAFT NEPHROPATHY: A PART OF THE GENERAL TRANSPLANT PHYSICAL EXAM. Transplantation, 2004, 78, 281.	1.0	0
484	When the Left Got Left Behind. American Journal of Gastroenterology, 2009, 104, 2644-2645.	0.4	0
485	Nonalcoholic Steatohepatitis (NASH). , 2010, 15, 65-71.		0
486	Acute right upper quadrant pain: A lesson in odds. Digestive and Liver Disease, 2010, 42, 72-73.	0.9	0

#	Article	IF	CITATIONS
487	Markers of Microbial Translocation Are Elevated in Hepatitis B (HBV) and Hepatitis C (HCV) Infection; A Window Into Biology and Surrogate Markers for Detecting Disease Progression. Gastroenterology, 2011, 140, S-897.	1.3	O
488	Liver Injury Due to Drugs and Herbal Agents. , 2011, , 311-352.		0
489	Reply:. Hepatology, 2011, 53, 2143-2143.	7.3	0
490	To resect or not to resect? That is the question. Gut, 2011, 60, 1177-1177.	12.1	0
491	HDV1 Oâ€04: Molecular characterization of hepatitis D virus associated hepatocellular carcinoma. Journal of Viral Hepatitis, 2015, 22, 2-3.	2.0	0
492	LP36: Understanding hepatitis delta virus and HBsAG kinetics during treatment with prenylation inhibitor lonafarnib via mathematical modeling. Journal of Hepatology, 2015, 62, S281-S282.	3.7	0
493	Mo1564 Automated Method to Detect and Quantify Lobular Inflammation and Portal Inflammation in Human Liver Biopsy Images. Gastroenterology, 2016, 150, S1146.	1.3	O
494	942 Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal Dystrophy (APECED)-Related Hepatitis: Variant of Autoimmune Hepatitis or New Clinical Entity?. Gastroenterology, 2016, 150, S1053.	1.3	0
495	Tu1725 Deficiency of Adenosine Deaminase 2 (DADA2); A Rare Cause of Hepatoportal Sclerosis and Non-Cirrhotic Portal Hypertension. Gastroenterology, 2016, 150, S1172-S1173.	1.3	0
496	Hepatobiliary and Pancreatic: Not all that "Glisson's―is fat. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1515-1515.	2.8	0
497	A Wolf in Sheep's Clothing in the Era of Non-Invasive Staging: Non-Hodgkin's Lymphoma Masquerading as Serologic HCV Cirrhosis. American Journal of Gastroenterology, 2017, 112, 398-399.	0.4	O
498	High angiopoietin-2 and suppression of tumorigenicity-2 levels correlate with onset of sinusoidal obstructive syndromeâ€"implication for the utility of serial biomarker monitoring. Bone Marrow Transplantation, 2017, 52, 926-928.	2.4	0
499	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Coinfected with Human Immunodeficiency Virus (HIV). Gastroenterology, 2017, 152, S27.	1.3	O
500	Reply:. Hepatology, 2019, 70, 2241-2242.	7.3	0
501	Letter to the Editor: Quantitative Histological Assessment in Nonalcoholic Fatty Liver Disease. Hepatology, 2020, 72, 785-785.	7.3	O
502	Fifty years of impact on liver pathology: a history of the Gnomes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 191-200.	2.8	0
503	Translational Research in Composite Tissue Allotransplantation. , 2008, , 43-54.		O
504	Abstract 2452: Generation of hepatocellular carcinomas with cancer stem cell properties from primary mouse hepatocytes. , $2011$ , , .		0

#	Article	IF	CITATIONS
505	Abstract 2653: Direct oncogenic reprogramming of adult mouse hepatocytes into cancer stem cells , 2013, , .		O
506	Abstract 2653: Tremelimimab plus tumor ablation for patients with hepatocellular carcinoma: Clinical results, immunomonitoring analysis of peripheral T cells and tumor biopsies. , 2016, , .		0
507	Abstract 818: Shortened telomere length in hepatocellular carcinoma in the United States. , 2016, , .		O
508	Tremelimumab: A monoclonal antibody against CTLA-4—In combination with radiofrequency ablation (RFA) in patients with biliary tract carcinoma (BTC) Journal of Clinical Oncology, 2017, 35, 88-88.	1.6	0
509	Innumerable Liver Lesions With a More Benign Outcome: A Case Report. American Journal of Gastroenterology, 2018, 113, S1338-S1339.	0.4	O
510	Letter: nonâ€invasive prediction models to exclude cirrhosis in <scp>NAFLD</scp> —not everyone fits the mould. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 56, 182-183.	3.7	0